Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBP NASDAQ:TENX NASDAQ:THAR NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.51-6.0%$0.42$0.22▼$15.80$25.35M0.8428.26 million shs748,234 shsTENXTenax Therapeutics$5.99-0.2%$5.97$3.25▼$7.89$27.35M1.4415,871 shs10,063 shsTHARTharimmune$3.68-7.8%$2.48$0.95▼$9.08$20.94M1.5630.98 million shs2.38 million shsVIVSVivoSim Labs$2.51+11.1%$1.93$1.41▼$21.96$6.53M1.11755,805 shs157,793 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma0.00%-11.02%+53.54%+34.53%+51,189,900.00%TENXTenax Therapeutics0.00%0.00%+0.17%-1.16%+56.81%THARTharimmune0.00%-38.15%+192.06%+143.72%+23.91%VIVSVivoSim Labs0.00%+2.87%+43.67%+36.41%+250,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.51-6.0%$0.42$0.22▼$15.80$25.35M0.8428.26 million shs748,234 shsTENXTenax Therapeutics$5.99-0.2%$5.97$3.25▼$7.89$27.35M1.4415,871 shs10,063 shsTHARTharimmune$3.68-7.8%$2.48$0.95▼$9.08$20.94M1.5630.98 million shs2.38 million shsVIVSVivoSim Labs$2.51+11.1%$1.93$1.41▼$21.96$6.53M1.11755,805 shs157,793 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma0.00%-11.02%+53.54%+34.53%+51,189,900.00%TENXTenax Therapeutics0.00%0.00%+0.17%-1.16%+56.81%THARTharimmune0.00%-38.15%+192.06%+143.72%+23.91%VIVSVivoSim Labs0.00%+2.87%+43.67%+36.41%+250,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/ATENXTenax Therapeutics 3.25Buy$17.00183.81% UpsideTHARTharimmune 3.50Strong Buy$17.00361.96% UpsideVIVSVivoSim Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VIVS, ASBP, TENX, and THAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025TENXTenax TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $14.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$26.99 per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/AVIVSVivoSim Labs$140K46.61N/AN/A$5.54 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-737.96%N/ATENXTenax Therapeutics-$17.60M-$0.92N/AN/AN/AN/A-31.34%-30.39%11/12/2025 (Estimated)THARTharimmune-$12.20M-$6.10N/A∞N/AN/A-1,239.20%-365.06%N/AVIVSVivoSim Labs-$2.48M-$10.20N/A∞N/A-1,396.48%-32.95%-21.31%N/ALatest VIVS, ASBP, TENX, and THAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025THARTharimmune-$0.58-$0.64-$0.06-$0.64N/AN/A8/13/2025Q2 2025ASBPAspire BiopharmaN/A-$0.04N/A-$0.04N/AN/A8/13/2025Q2 2025TENXTenax Therapeutics-$0.50-$0.27+$0.23-$0.27N/AN/A8/12/2025Q1 2026VIVSVivoSim LabsN/A-$1.14N/A-$1.14N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.090.09TENXTenax TherapeuticsN/A41.8941.89THARTharimmuneN/A1.171.17VIVSVivoSim LabsN/A4.524.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%TENXTenax Therapeutics1.67%THARTharimmune1.16%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%TENXTenax Therapeutics3.14%THARTharimmune10.01%VIVSVivoSim Labs3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/ATENXTenax Therapeutics94.56 million4.42 millionNot OptionableTHARTharimmune25.69 million5.12 millionNot OptionableVIVSVivoSim Labs202.60 million2.50 millionN/AVIVS, ASBP, TENX, and THAR HeadlinesRecent News About These CompaniesVivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | finanznachrichten.deVivoSim appoints Lialin as Chief Commercial OfficerAugust 14, 2025 | msn.comVivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing ServicesAugust 14, 2025 | quiverquant.comQVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | financialpost.comFVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | globenewswire.comVivoSim: Fiscal Q1 Earnings SnapshotAugust 12, 2025 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIVS, ASBP, TENX, and THAR Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.51 -0.03 (-6.04%) As of 09/5/2025 04:00 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.Tenax Therapeutics NASDAQ:TENX$5.99 -0.01 (-0.17%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.98 0.00 (-0.08%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Tharimmune NASDAQ:THAR$3.68 -0.31 (-7.77%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.70 +0.02 (+0.43%) As of 09/5/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.VivoSim Labs NASDAQ:VIVS$2.51 +0.25 (+11.06%) As of 09/5/2025 04:00 PM EasternOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
